Generali Asset Management SPA SGR Trims Holdings in Cencora, Inc. $COR

Generali Asset Management SPA SGR lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 54.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,779 shares of the company’s stock after selling 15,199 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Cencora were worth $3,994,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Golden State Equity Partners grew its holdings in Cencora by 3.0% during the 3rd quarter. Golden State Equity Partners now owns 1,761 shares of the company’s stock worth $550,000 after acquiring an additional 51 shares in the last quarter. Financial Consulate Inc. bought a new position in shares of Cencora during the third quarter worth about $362,000. Salomon & Ludwin LLC grew its stake in Cencora by 638.1% in the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after purchasing an additional 134 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its holdings in Cencora by 30.5% in the third quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,971 shares of the company’s stock valued at $616,000 after buying an additional 461 shares during the last quarter. Finally, Delta Investment Management LLC acquired a new stake in Cencora during the third quarter valued at approximately $426,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,317 shares of company stock valued at $7,009,260 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

COR has been the subject of several research reports. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective for the company. UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Robert W. Baird set a $392.00 price objective on shares of Cencora in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $373.25.

Cencora Stock Performance

Shares of COR opened at $338.87 on Friday. The firm has a fifty day moving average of $349.59 and a 200-day moving average of $316.54. The company has a market cap of $65.74 billion, a price-to-earnings ratio of 42.63, a price-to-earnings-growth ratio of 1.61 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $225.75 and a 1 year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. Cencora’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.